Cargando…

Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance

Immune checkpoint blockade (ICB) has rapidly transformed the treatment paradigm for various cancer types. Multiple single or combinations of ICB treatments have been approved by the US Food and Drug Administration, providing more options for patients with advanced cancer. However, most patients coul...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiaoting, Ni, Yanghong, Liang, Xiao, Lin, Yi, An, Biao, He, Xiang, Zhao, Xia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520263/
https://www.ncbi.nlm.nih.gov/pubmed/36189283
http://dx.doi.org/10.3389/fimmu.2022.915094
_version_ 1784799584645545984
author Zhou, Xiaoting
Ni, Yanghong
Liang, Xiao
Lin, Yi
An, Biao
He, Xiang
Zhao, Xia
author_facet Zhou, Xiaoting
Ni, Yanghong
Liang, Xiao
Lin, Yi
An, Biao
He, Xiang
Zhao, Xia
author_sort Zhou, Xiaoting
collection PubMed
description Immune checkpoint blockade (ICB) has rapidly transformed the treatment paradigm for various cancer types. Multiple single or combinations of ICB treatments have been approved by the US Food and Drug Administration, providing more options for patients with advanced cancer. However, most patients could not benefit from these immunotherapies due to primary and acquired drug resistance. Thus, a better understanding of the mechanisms of ICB resistance is urgently needed to improve clinical outcomes. Here, we focused on the changes in the biological functions of CD8(+) T cells to elucidate the underlying resistance mechanisms of ICB therapies and summarized the advanced coping strategies to increase ICB efficacy. Combinational ICB approaches and individualized immunotherapies require further in-depth investigation to facilitate longer-lasting efficacy and a more excellent safety of ICB in a broader range of patients.
format Online
Article
Text
id pubmed-9520263
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95202632022-09-30 Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance Zhou, Xiaoting Ni, Yanghong Liang, Xiao Lin, Yi An, Biao He, Xiang Zhao, Xia Front Immunol Immunology Immune checkpoint blockade (ICB) has rapidly transformed the treatment paradigm for various cancer types. Multiple single or combinations of ICB treatments have been approved by the US Food and Drug Administration, providing more options for patients with advanced cancer. However, most patients could not benefit from these immunotherapies due to primary and acquired drug resistance. Thus, a better understanding of the mechanisms of ICB resistance is urgently needed to improve clinical outcomes. Here, we focused on the changes in the biological functions of CD8(+) T cells to elucidate the underlying resistance mechanisms of ICB therapies and summarized the advanced coping strategies to increase ICB efficacy. Combinational ICB approaches and individualized immunotherapies require further in-depth investigation to facilitate longer-lasting efficacy and a more excellent safety of ICB in a broader range of patients. Frontiers Media S.A. 2022-09-15 /pmc/articles/PMC9520263/ /pubmed/36189283 http://dx.doi.org/10.3389/fimmu.2022.915094 Text en Copyright © 2022 Zhou, Ni, Liang, Lin, An, He and Zhao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhou, Xiaoting
Ni, Yanghong
Liang, Xiao
Lin, Yi
An, Biao
He, Xiang
Zhao, Xia
Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
title Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
title_full Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
title_fullStr Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
title_full_unstemmed Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
title_short Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
title_sort mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520263/
https://www.ncbi.nlm.nih.gov/pubmed/36189283
http://dx.doi.org/10.3389/fimmu.2022.915094
work_keys_str_mv AT zhouxiaoting mechanismsoftumorresistancetoimmunecheckpointblockadeandcombinationstrategiestoovercomeresistance
AT niyanghong mechanismsoftumorresistancetoimmunecheckpointblockadeandcombinationstrategiestoovercomeresistance
AT liangxiao mechanismsoftumorresistancetoimmunecheckpointblockadeandcombinationstrategiestoovercomeresistance
AT linyi mechanismsoftumorresistancetoimmunecheckpointblockadeandcombinationstrategiestoovercomeresistance
AT anbiao mechanismsoftumorresistancetoimmunecheckpointblockadeandcombinationstrategiestoovercomeresistance
AT hexiang mechanismsoftumorresistancetoimmunecheckpointblockadeandcombinationstrategiestoovercomeresistance
AT zhaoxia mechanismsoftumorresistancetoimmunecheckpointblockadeandcombinationstrategiestoovercomeresistance